Chapter/Section Purchase

1 Study Coverage
1.1 Myotonic Dystrophy Drug Product Introduction
1.2 Market by Type
1.2.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Market by Distribution Channel
1.3.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Myotonic Dystrophy Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Myotonic Dystrophy Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Myotonic Dystrophy Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Myotonic Dystrophy Drug Sales by Region
2.4.1 Global Myotonic Dystrophy Drug Sales by Region (2017-2022)
2.4.2 Global Sales Myotonic Dystrophy Drug by Region (2023-2028)
2.5 Global Myotonic Dystrophy Drug Revenue by Region
2.5.1 Global Myotonic Dystrophy Drug Revenue by Region (2017-2022)
2.5.2 Global Myotonic Dystrophy Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Myotonic Dystrophy Drug Sales by Manufacturers
3.1.1 Global Top Myotonic Dystrophy Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Myotonic Dystrophy Drug in 2021
3.2 Global Myotonic Dystrophy Drug Revenue by Manufacturers
3.2.1 Global Myotonic Dystrophy Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Drug Revenue in 2021
3.3 Global Myotonic Dystrophy Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Myotonic Dystrophy Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Myotonic Dystrophy Drug Sales by Type
4.1.1 Global Myotonic Dystrophy Drug Historical Sales by Type (2017-2022)
4.1.2 Global Myotonic Dystrophy Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Type (2017-2028)
4.2 Global Myotonic Dystrophy Drug Revenue by Type
4.2.1 Global Myotonic Dystrophy Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Myotonic Dystrophy Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2017-2028)
4.3 Global Myotonic Dystrophy Drug Price by Type
4.3.1 Global Myotonic Dystrophy Drug Price by Type (2017-2022)
4.3.2 Global Myotonic Dystrophy Drug Price Forecast by Type (2023-2028)
5 Market Size by Distribution Channel
5.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel
5.1.1 Global Myotonic Dystrophy Drug Historical Sales by Distribution Channel (2017-2022)
5.1.2 Global Myotonic Dystrophy Drug Forecasted Sales by Distribution Channel (2023-2028)
5.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2017-2028)
5.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel
5.2.1 Global Myotonic Dystrophy Drug Historical Revenue by Distribution Channel (2017-2022)
5.2.2 Global Myotonic Dystrophy Drug Forecasted Revenue by Distribution Channel (2023-2028)
5.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2017-2028)
5.3 Global Myotonic Dystrophy Drug Price by Distribution Channel
5.3.1 Global Myotonic Dystrophy Drug Price by Distribution Channel (2017-2022)
5.3.2 Global Myotonic Dystrophy Drug Price Forecast by Distribution Channel (2023-2028)
6 North America
6.1 North America Myotonic Dystrophy Drug Market Size by Type
6.1.1 North America Myotonic Dystrophy Drug Sales by Type (2017-2028)
6.1.2 North America Myotonic Dystrophy Drug Revenue by Type (2017-2028)
6.2 North America Myotonic Dystrophy Drug Market Size by Distribution Channel
6.2.1 North America Myotonic Dystrophy Drug Sales by Distribution Channel (2017-2028)
6.2.2 North America Myotonic Dystrophy Drug Revenue by Distribution Channel (2017-2028)
6.3 North America Myotonic Dystrophy Drug Market Size by Country
6.3.1 North America Myotonic Dystrophy Drug Sales by Country (2017-2028)
6.3.2 North America Myotonic Dystrophy Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Myotonic Dystrophy Drug Market Size by Type
7.1.1 Europe Myotonic Dystrophy Drug Sales by Type (2017-2028)
7.1.2 Europe Myotonic Dystrophy Drug Revenue by Type (2017-2028)
7.2 Europe Myotonic Dystrophy Drug Market Size by Distribution Channel
7.2.1 Europe Myotonic Dystrophy Drug Sales by Distribution Channel (2017-2028)
7.2.2 Europe Myotonic Dystrophy Drug Revenue by Distribution Channel (2017-2028)
7.3 Europe Myotonic Dystrophy Drug Market Size by Country
7.3.1 Europe Myotonic Dystrophy Drug Sales by Country (2017-2028)
7.3.2 Europe Myotonic Dystrophy Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Myotonic Dystrophy Drug Market Size by Type
8.1.1 Asia Pacific Myotonic Dystrophy Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Myotonic Dystrophy Drug Market Size by Distribution Channel
8.2.1 Asia Pacific Myotonic Dystrophy Drug Sales by Distribution Channel (2017-2028)
8.2.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Distribution Channel (2017-2028)
8.3 Asia Pacific Myotonic Dystrophy Drug Market Size by Region
8.3.1 Asia Pacific Myotonic Dystrophy Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Myotonic Dystrophy Drug Market Size by Type
9.1.1 Latin America Myotonic Dystrophy Drug Sales by Type (2017-2028)
9.1.2 Latin America Myotonic Dystrophy Drug Revenue by Type (2017-2028)
9.2 Latin America Myotonic Dystrophy Drug Market Size by Distribution Channel
9.2.1 Latin America Myotonic Dystrophy Drug Sales by Distribution Channel (2017-2028)
9.2.2 Latin America Myotonic Dystrophy Drug Revenue by Distribution Channel (2017-2028)
9.3 Latin America Myotonic Dystrophy Drug Market Size by Country
9.3.1 Latin America Myotonic Dystrophy Drug Sales by Country (2017-2028)
9.3.2 Latin America Myotonic Dystrophy Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Myotonic Dystrophy Drug Market Size by Type
10.1.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Myotonic Dystrophy Drug Market Size by Distribution Channel
10.2.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Distribution Channel (2017-2028)
10.2.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Distribution Channel (2017-2028)
10.3 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country
10.3.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Lupin
11.1.1 Lupin Corporation Information
11.1.2 Lupin Overview
11.1.3 Lupin Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Lupin Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Lupin Recent Developments
11.2 Teva
11.2.1 Teva Corporation Information
11.2.2 Teva Overview
11.2.3 Teva Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Teva Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Teva Recent Developments
11.3 ANI Pharmaceuticals
11.3.1 ANI Pharmaceuticals Corporation Information
11.3.2 ANI Pharmaceuticals Overview
11.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 ANI Pharmaceuticals Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Overview
11.4.3 Mylan Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Mylan Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Corporation Information
11.6.2 Sun Pharma Overview
11.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Sun Pharma Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sun Pharma Recent Developments
11.7 Mallinckrodt
11.7.1 Mallinckrodt Corporation Information
11.7.2 Mallinckrodt Overview
11.7.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Mallinckrodt Myotonic Dystrophy Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Mallinckrodt Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Myotonic Dystrophy Drug Industry Chain Analysis
12.2 Myotonic Dystrophy Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myotonic Dystrophy Drug Production Mode & Process
12.4 Myotonic Dystrophy Drug Sales and Marketing
12.4.1 Myotonic Dystrophy Drug Sales Channels
12.4.2 Myotonic Dystrophy Drug Distributors
12.5 Myotonic Dystrophy Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Myotonic Dystrophy Drug Industry Trends
13.2 Myotonic Dystrophy Drug Market Drivers
13.3 Myotonic Dystrophy Drug Market Challenges
13.4 Myotonic Dystrophy Drug Market Restraints
14 Key Findings in The Global Myotonic Dystrophy Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer